Last week saw a number of broker notes hitting the wires once again. Three buy ratings that investors might want to be aware of are summarised below.
Here's why brokers think investors ought to buy them next week:
CSL Limited (ASX: CSL)
According to a note out of Macquarie, its analysts have retained their outperform rating and $340.00 price target on this biotherapeutics company's shares. Macquarie is feeling positive about CSL's outlook thanks to improving plasma collection yields. It expects this to boost its margins in the coming years. In addition, it highlights that CSL's research and development pipeline should also be supportive. The CSL share price ended the week at $288.49.
New Hope Corporation Limited (ASX: NHC)
Another note out of Macquarie reveals that its analysts have retained their outperform rating and $6.00 price target on this coal miner's shares. While New Hope's half-year results and dividend fell short of expectations, the broker remains positive. Particularly given the strength of the Bengalla operation, its organic growth opportunities, and potential M&A activities. The New Hope share price was fetching $5.49 at the end of the week.
Nextdc Ltd (ASX: NXT)
Analysts at Citi have retained their buy rating on this data centre operator's shares with an improved price target of $12.70. This follows a post-earnings season review of the tech sector by the broker. The good news is that Citi remains positive following the review. The broker revealed that it likes NextDC due to its strong revenue growth outlook, which is being supported by a combination of strong demand and inflation-linked contracts. The NextDC share price ended the week at $10.06.
